linjc16/ctgov huggingface dataset:
Radiologic Score and Failure of Conservative Management of Adhesive Small Bowel Obstruction

Study Overview
=================
Brief Summary
-----------------
The management of acute adhesive small bowel obstruction remains challenging for the digestive surgeon. The Bologna guidelines recommend that conservative management of aSBO. The literature reports that this form of management has a failure rate between 10 and 40%. A radiological score has been proposed and was associated with an increased risk of failure of conservative management. This tool is promising to select patients further requiring surgery but it has to be assessed in a multi centric prospective cohort.

Official Title
-----------------
Assessment of a Predictive Radiologic Score to Predict the Failure of the Non-operative Management of Adhesive Small Bowel Obstruction: a Prospective Cohort Analysis

Conditions
-----------------
Small Bowel Obstruction, Conservative Management, Imaging

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all the consecutive patients admitted for initial non-surgical management for aSBO during the period of inclusion Exclusion Criteria: the cause of SBO was functional or other than adhesive patients requiring initial surgical management. absence of computed tomography performed at admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| success of the medical management<br>Patients that recovered flatus and stools, and that tolerated solid food within the 3 days after the admission | |
| failure of the medical management<br>Patients that did not recover flatus and stools, and that did not tolerate solid food within the 3 days after the admission. These patients had an indication for surgery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Angers CT score | The Angers CT score ≥5 was considered to be risk factor for failure of the medical management. Angers CT score was calculated by reading the CT scan as follow: beak sign (+2), if not (0) closed loop (+4), if not (0) focal (+4) or diffuse (+4) intraperitoneal liquid, if not (0) focal (+2) or diffuse (0) mesenteric haziness, if not (0) focal (-3) or diffuse (-3) mesenteric liquid, if not (0) diameter of the most dilated small bowel loop > 40 mm (-2) (if not (0). | immediately after the completion of the CT-scan |
Zilver PTX Delivery System

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the performance of the Zilver PTX stent thumbwheel delivery system.

Official Title
-----------------
Zilver Paclitaxel(PTX) Thumbwheel Delivery System

Conditions
-----------------
Peripheral Vascular Disease

Intervention / Treatment
-----------------
* Device: Zilver® PTX® Drug-Eluting Peripheral Stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has symptomatic vascular disease of the native above-the-knee femoropopliteal arteries Patient has atherosclerotic lesion of the above-the-knee femoropopliteal artery Exclusion Criteria: Patient is < 18 years of age Patient unable to complete required follow-up assessments Patient unwilling to sign and date the informed consent Simultaneous participation in another investigational drug or device study Pregnant, breastfeeding or planning to become pregnant in the next 5 years Additional medical/anatomical restrictions as specified in the Clinical Investigation Plan

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Drug Eluting Stent<br>Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent | Device: Zilver® PTX® Drug-Eluting Peripheral Stent<br>* Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Percent Change in Stent Length Upon Deployment |  | Immediately following completion of the stent placement procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Peripheral Vascular Disease, Femoral Artery, Drug-Eluting Stent
Effect of Perioperative Hypothermia on Postoperative Pain

Study Overview
=================
Brief Summary
-----------------
This study aims to observe the impact of perioperative body temperature on postoperative pain and pain sensitization for the patients with laparoscopic surgery. Based on this study the investigators aimed to explore the effect of perioperative hypothermia on postoperative pain.

Detailed Description
-----------------
This study aims to included surgery patients to observe the impact of perioperative body temperature on postoperative pain and pain sensitization for the patients with laparoscopic surgery. Body temperature and postoperative pain will be continuously assessed, and then association analysis will be performed.

Official Title
-----------------
The Effect of Perioperative Hypothermia on Postoperative Pain and Pain Sensitization With Laparoscopic Surgery: a Prospective Observational Study

Conditions
-----------------
Postoperative Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-70 years old American society of anesthesiologists I-III Patients who plan to laparoscopic surgery under general anesthesia Volunteer to participate in this study and sign informed consent. Exclusion Criteria: the patient with chronic pain Patients with fever The patient is infected Severe vision, hearing, language impairment or other reasons unable to communicate with visitors Patients with known mental illness or lack of communication or cognitive impairment before operation; Long-term use of sedatives, antidepressants or alcoholism Artificial cooling and low temperature protection were taken during the operation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' pain score after surgery | The patients' pain score was tested with Numerical analogue scale of pain (0-10, 0 represents pain free, and 10 represents unbearable pain). | From ending of the surgery to 24 hours after anesthetic resuscitation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' pain score during postanesthesia care unit | The patients' pain score was tested with Numerical analogue scale of pain (0-10, 0 represents pain free, and 10 represents unbearable pain). | From ending of the surgery to the time when discharge from postanesthesia care unit with a mean of 30 minutes after surgery | 
| Pressure pain threshold | the patients' pain threshold was tested by tenderness meter. | From beginning of the surgery to the time when discharge from postanesthesia care unit with a mean of 30 minutes after surgery |
Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia

Study Overview
=================
Brief Summary
-----------------
Patients with diagnosis of HPIN were enrolled. Patients were randomized into two groups: dutasteride treatment group and watchful waiting strategy group. According to the study protocol the subjects would undergo 10 core biopsies after 6, 12, 24, and 36 months after randomization. There are assessed the rate of prostate cancer at repeated transrectal ultrasound guided biopsies and the effect of 5 alfa reductase inhibitor (dutasteride) on prevention of prostate cancer development for patients with high grade intraepithelial neoplasia (HPIN).

Official Title
-----------------
Effect of 5α Reductase Inhibitor Dutasteride on the Prevention of the Prostate Cancer in Men With High Grade Intraepithelial Neoplasia of the Prostate

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: dutasteride
* Procedure: prostate biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age - 40-80 years HPIN on prostate biopsy specimens PSA below 20ng/ml No hormone therapy or radiation in pelvic region No previous treatment with 5alfa reductase inhibitors Signed Subject Information and Informed Subject Consent Form. Exclusion Criteria: 1. Not compensate cardiovascular, pulmonary, hepatic or renal functions, neurological, psychiatric disease, sepsis, etc.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dutasteride<br>treatment group | Drug: dutasteride<br>* 0.5mg<br>Procedure: prostate biopsy<br>* prostate biopsy<br>|
| Active Comparator: watchful waiting strategy<br> | Procedure: prostate biopsy<br>* prostate biopsy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of prostate cancer at repeated transrectal ultrasound guided biopsies in case of HPIN |  | 6, 12, 24, and 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effect of 5 alfa reductase inhibitor (dutasteride) on prevention of prostate cancer development for patients with high grade intraepithelial neoplasia (HPIN). |  | 6, 12, 24, and 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prostate cancer, chemoprevention, dutasteride
Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases

Study Overview
=================
Brief Summary
-----------------
Tocilizumab and Sarilumab are first-line biological disease-modifying anti-rheumatic drug (bDMARD) which inhibits Interleukin 6 (IL-6) pathway through blockade of its receptor on the treatment of Rheumatoid Arthritis and other rheumatic diseases as Giant Cell Arteritis, Still's disease and Idiopathic Juvenile Arthritis. At present, there is a lack of evidence to recommend the treatment of one bDMARD over another. Seeking for genetic biomarkers to predict response to treatment could be key towards a personalized treatment strategy in rheumatology. The investigators aime to evaluate whether functional single nucleotide polymorphisms (SNPs) in the IL6R gene could predict response and/or toxicity in patients with rheumatic diseases treated with anti-IL-6 receptor drugs.

Official Title
-----------------
Observational Retrospective Studies on Single Nucleotide Variants (SNPs) on the Interleukin-6 Receptor (IL6R) and Their Influence on the Response to Treatment and Safety in Patients With Specific Rheumatic Diseases

Conditions
-----------------
Rheumatoid Arthritis, Idiopathic Juvenile Arthritis, Giant Cell Arteritis, Still Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Rheumatoid Arthritis by the American College of Rheumatology (ACR) 2010 criteria or Diagnosis of Giant Cell Arteritis by the International League of Associations for Rheumatology (ILAR) criteria or Diagnosis of Still disease by classification criteria (Yamaguchi et al.) or Diagnosis of Idiopathic Juvenile Arthritis by ACR 1990 criteria. All of the previous must have been treated with anti-IL-6R monoclonal antibodies in the last 5 years Exclusion Criteria: <18 years at recruitment Another rheumatic disease different of the ones in the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DAS28-C-reactive Protein (CRP) change | Activity measure for patients with Rheumatoid Arthritis (RA) | at 6 months | 
| Rate of adverse events | Known adverse events during treatment with anti-IL6R drugs | During treatment with anti-IL6R drugs | 
| CRP change | Acute phase reactant reduction in the other diseases different of RA. | 6 months | 
| Erythrocyte sedimentation rate (ESR) change | Acute phase reactant reduction in the other diseases different of RA. | 6 months |
Clinical Results of Implant-retained Mandibular Overdentures in Edentulous Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the clinical results of implant-retained mandibular overdentures in edentulous patients.

Detailed Description
-----------------
The survival of implants,condition of the peri-implant soft tissue were evaluated. And patients' perceptions regarding the outcome were assessed on visual analog scales (VAS), oral health impact profile-14 (OHIP) and semantic differential scale questionnaires.

Official Title
-----------------
Clinical Results of Implant-retained Mandibular Overdentures in Edentulous Patients: A 5-year Retrospective Study

Conditions
-----------------
Edentulous

Intervention / Treatment
-----------------
* Device: implant-retained overdentures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated with implant retained overdentures With the ability to read and sign the informed consent document Exclusion Criteria: Jaw radiotherapy treatment before and after implanting Patients who suffered with mental and psychological disease will influence their oral health normal maintenance Can not read and sign the informed consent document

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 83 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| implant retained-overdentures with the attachment of bar<br>patients treated with implant-retained overdentures,and the attachment is bar | Device: implant-retained overdentures<br>* patients treated with an implant-retained overdenture in the mandible<br>|
| implant retained-overdentures with the attachment of magnet<br>patients treated with implant-retained overdentures,and the attachment is magnet | Device: implant-retained overdentures<br>* patients treated with an implant-retained overdenture in the mandible<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival of implants |  | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gingival Bleeding on Probing | Gingival bleeding on probing (BOP) using the modified sulcus bleeding index for implants. Scale equals 0 = No bleeding when periodontal probe is passed along the gingival margin;1 = Isolated bleeding spots visible;2 = Blood forms a confluent red line on the gingival margin;3 = Heavy or profuse bleeding | through study completion, an average of 1 year | 
| Pocket depths | Pocket depths measured around implants in millimeter (mm) | through study completion, an average of 1 year | 
| Marginal bone loss |  | through study completion, an average of 1 year |
Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
Participants enrolled at the Alzheimer's Disease Research Center (ADRC) at Wake Forest School of Medicine will be invited to take part in this study. The purpose of this study is to identify and measure the amount of a protein called amyloid in the brain.It is thought that the build up of amyloid may be related to the development of Alzheimer's disease.

Detailed Description
-----------------
Brain amyloid will be measured using PET with [11C]PiB. Participation will involve an initial brain scan and possibly a follow-up brain scan two years later. The data collected in this study will help explain amyloid deposits in several groups of participants including adults with and without signs of memory impairment. The information collected will help find out who is more likely to have brain amyloid and when it increases the risk for developing memory problems. Research studies suggest that people with elevated levels of brain amyloid are at an increased risk for memory decline, but this does not mean that every person with amyloid build up will develop AD.

Official Title
-----------------
Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease

Conditions
-----------------
Alzheimer Disease, Mild Cognitive Impairment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Enrolled in a study with the Alzheimer's Disease Research Center. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amyloid deposition | Studying the initial amyloid deposition in participants as well as their rate of amyloid accumulation over time will help establish whether there is an early therapeutic window for intervention in high risk patients. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Memory
Metabolomic Analysis of Exhaled Breath Condensates in Patients With COPD and Bronchiectasis

Study Overview
=================
Brief Summary
-----------------
Metabolomics is a large-scale approach to monitoring the compounds involved in cellular processes. It may reflect changes in biological function. Collection of exhaled breath is a newly developed, noninvasive method that may allow clinicians and researchers to assess biochemical profiles in the airway. This study is conducted for the metabolomic analysis of the exhaled gas in patients with Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis.

Detailed Description
-----------------
Metabolomics is a large-scale approach to monitoring as many as possible of the compounds involved in cellular processes in a single assay to derive metabolic profiles. Compared with genomics or proteomics, metabolomics reflects changes in phenotype and therefore function. Collection of exhaled breath condensate (EBC) is a newly developed, noninvasive method that may allow clinicians and researchers to assess biochemical profiles in the alveolar lining fluid. The aims of this study are: (1)Collecting and metabolomic profiling of the EBCs from patients with COPD/bronchiectasis; (2) Comparing the profiles of these patients obtained during stable and acute exacerbation periods; (3) Comparing the profiles of these patients with and without Pseudomonas colonization/infection; (4) Correlation of EBC metabolomic profiles with clinical phenotypes, severity and outcomes of these patients.

Official Title
-----------------
Exhaled Breath Analysis in Patients With COPD and Bronchiectasis

Conditions
-----------------
COPD, Bronchiectasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with COPD or bronchiectasis Exclusion Criteria: not willing to sign ICF

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD<br>COPD | |
| Bronchiectasis<br>Bronchiectasis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, Bronchiectasis, Metabolomics